Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,296.00
(
-1.79%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.13
(
3.54%
)
Bitcoin
70,024.00
(
0.18%
)
News Focus
News Focus
Post# of 257263
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: DewDiligence post# 150886

Thursday, 10/18/2012 8:18:23 PM

Thursday, October 18, 2012 8:18:23 PM

Post# of 257263

The latest info on Presidio’s PPI-668 (an NS5A inhibitor) are the 3-day monotherapy data reported in Jun 2012 (#msg-76993511).

Not sure off-hand how that compares to NS5A 3-day data from others.

All told, therefore, combining these two HCV drugs does not exactly seem like a winning formula for commercial success.

What's that saying of yours? Something about two turkeys? ; )
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today